Welcome to our dedicated page for Nuvation Bio SEC filings (Ticker: NUVB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvation Bio Inc. filings document the regulatory record of a public oncology company with Class A common stock listed on the New York Stock Exchange. The company's 8-K disclosures cover operating and financial results, material agreements, clinical and regulatory updates for taletrectinib and safusidenib, pipeline decisions involving its drug-drug conjugate program, and other material-event disclosures.
Proxy materials describe board elections, auditor ratification, executive compensation votes, shareholder voting procedures, and governance matters. Capital-structure filings identify the company's registered securities, including Class A common stock and historical warrant-related disclosures, while Form 25 records document removal of a warrant class from exchange listing and registration.
Nuvation Bio Inc. reported that Chief Regulatory Officer Kerry Wentworth received a grant of stock options covering 748,130 shares of common stock on February 27, 2026. The option has an exercise price of $0.00 per share and vests 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to continued service. Following this grant, Wentworth also holds 53,000 shares of Class A common stock, including 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest as to 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to her continuous service. Following this grant, she directly owned 84,000 shares of Class A common stock, which includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that Chief Financial Officer Philippe Sauvage received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to his continuous service.
Following this grant, Sauvage directly holds 12,673 shares of Class A common stock. This total includes 2,771 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Nuvation Bio Inc. reported that its Chief People Officer, Markel Stacy, was granted a stock option covering 748,130 shares of Class A common stock on February 27, 2026. The option vests 25% on the one-year anniversary of February 27, 2026 and then monthly over the following 36 months, contingent on her continued service.
After this grant, Stacy holds 748,130 stock options and 32,591 shares of Class A common stock directly, including 3,000 shares acquired on November 19, 2025 under the company’s 2021 Employee Stock Purchase Plan.
Cui Xiangmin reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that director Xiangmin Cui received a grant of stock options covering 74,813 shares on February 27, 2026. The options have a grant price of $0.00 per share and represent a right to buy company stock rather than immediate ownership.
According to the terms, the option vests as to 1/24 of the shares on the one-month anniversary of January 1, 2026, and then monthly over the following 23 months, as long as Cui remains in continuous service on each vesting date. After this grant, Cui holds 74,813 stock options directly.
Hattersley Gary reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that its Chief Scientific Officer, Gary Hattersley, received a grant of stock options covering 748,130 shares of common stock. The options were awarded at a grant price of $0.00 per option, reflecting a non-cash compensation award rather than an open-market purchase.
According to the vesting terms, 25% of the option grant will vest on the one-year anniversary of 2/27/2026, with the remaining portion vesting in equal monthly installments over the following 36 months, subject to his continuous service on each vesting date.
Nuvation Bio Inc. reported that its Chief Technical Operations officer, David C. Hanley, received a grant of 748,130 stock options. These options were acquired as a derivative security award and increase his directly held option position to 748,130 options.
According to the terms, the option vests as to 25% on the one-year anniversary of February 27, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on Hanley’s continuous service on each vesting date.
Hung David reported acquisition or exercise transactions in this Form 4 filing.
Nuvation Bio Inc. reported that President and CEO David Hung received a grant of stock options covering 1,995,012 shares. These options were awarded at no cash cost to him as a grant, not an open-market purchase.
According to the disclosure, the option vests 25% on the one-year anniversary of 2/27/2026, with the remaining shares vesting monthly over the following 36 months, as long as he continues in service on each vesting date.
Nuvation Bio Inc. is a clinical-stage oncology company that has transitioned into a commercial organization with the U.S. launch of IBTROZI (taletrectinib) in June 2025 for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer. IBTROZI is also approved in Japan and China through partners, supported by strong Phase 2 data showing high objective response rates and long durations of response in both TKI‑naïve and TKI‑pretreated patients. The company has structured global licensing deals with Innovent, Nippon Kayaku and Eisai that provide upfront payments, milestones and tiered royalties across major territories. Beyond taletrectinib, Nuvation is advancing safusidenib, a brain‑penetrant mutant IDH1 inhibitor, in a 300‑patient global Phase 3 SIGMA maintenance trial for high‑risk or high‑grade IDH1‑mutant astrocytoma, building on encouraging Phase 1–2 results in glioma. The company is also investing in a proprietary drug‑drug conjugate platform, relies on third‑party manufacturers, and highlights extensive patent coverage for taletrectinib and safusidenib with expected expiries into the 2030s and potential term extensions.
Nuvation Bio Inc. reported fourth-quarter and full-year 2025 results, highlighting the first commercial contributions from IBTROZI and stronger collaboration revenue. Net product revenue from U.S. sales of IBTROZI reached $15.7 million in Q4 and $24.7 million for 2025.
Total revenue rose to $41.9 million in Q4 and $62.9 million for 2025, driven by a $25 million milestone from Nippon Kayaku and higher license, service, supply and royalty revenue. The company ended 2025 with $529.2 million in cash, cash equivalents and marketable securities and reported a narrower full-year net loss of $204.6 million, or $(0.60) per share, compared with a $567.9 million loss in 2024.